Puma Biotechnology (PBYI) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Puma Biotechnology is projected to report its Q2 2025 earnings on August 7th, expecting earnings of $0.11 per share and $52 million in revenue.
• Analyst ratings have improved as Wall Street Zen upgraded the stock from a "buy" to a "strong-buy" rating recently.
• Insider trading activity includes significant sales by directors, with over 173,000 shares sold in the last 90 days, indicating potential concerns about insider confidence in the stock.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Puma Biotechnology to post earnings of $0.11 per share and revenue of $52.00 million for the quarter.

Puma Biotechnology Price Performance

Shares of NASDAQ:PBYI traded down $0.04 during trading on Friday, reaching $3.07. The stock had a trading volume of 230,766 shares, compared to its average volume of 308,127. Puma Biotechnology has a 1-year low of $2.22 and a 1-year high of $4.13. The stock has a market cap of $152.36 million, a PE ratio of 3.99 and a beta of 1.30. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.43 and a current ratio of 1.53. The business has a fifty day moving average price of $3.42 and a 200-day moving average price of $3.19.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd.

Insiders Place Their Bets

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 21,580 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $3.54, for a total transaction of $76,393.20. Following the sale, the chief executive officer owned 7,180,901 shares in the company, valued at approximately $25,420,389.54. This represents a 0.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jay M. Moyes sold 22,000 shares of the stock in a transaction on Friday, June 13th. The shares were sold at an average price of $3.40, for a total value of $74,800.00. Following the sale, the director owned 53,322 shares in the company, valued at approximately $181,294.80. This trade represents a 29.21% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 173,649 shares of company stock worth $596,914. 23.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Puma Biotechnology

Large investors have recently bought and sold shares of the stock. Royal Bank of Canada boosted its holdings in shares of Puma Biotechnology by 3.8% during the first quarter. Royal Bank of Canada now owns 85,999 shares of the biopharmaceutical company's stock worth $254,000 after purchasing an additional 3,117 shares during the last quarter. Invesco Ltd. raised its position in shares of Puma Biotechnology by 88.9% in the 1st quarter. Invesco Ltd. now owns 37,631 shares of the biopharmaceutical company's stock worth $111,000 after buying an additional 17,707 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Puma Biotechnology in the 1st quarter worth $66,000. Finally, AQR Capital Management LLC raised its position in shares of Puma Biotechnology by 366.5% in the 1st quarter. AQR Capital Management LLC now owns 50,458 shares of the biopharmaceutical company's stock worth $149,000 after buying an additional 39,641 shares during the period. Institutional investors and hedge funds own 61.29% of the company's stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.